Spisek et al. showed that tumor cells that were treated with bortezomib (a proteasome inhibitor) present increased expression of HSP90, which induces the upregulation of the maturation-associated markers CD80, CD83, and CD86 on DCs [90]. The gene discussed is CD80; the disease is neoplasm.